eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases

Copyright West LLC. Minimum 15 minutes delayed.

Recent News Releases
Eyenovia Reports Third Quarter 2019 Financial Results
Eyenovia Announces Conference Call and Webcast for Third Quarter 2019 Financial Results
Eyenovia Advances MicroLine for the Treatment of Presbyopia Towards Phase III Development and Reprioritizes Late-Stage Ophthalmology Pipeline
Upcoming Events
There are currently no events scheduled.